AbbVie (ABBV) stock-based compensation was $955M in FY2025 (+5% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$955M
+5%
2024
$911M
+22%
2023
$747M
+11%
2022
$671M
-3%
2021
$692M
-8%
2020
$753M
+75%
2019
$430M
+2%
2018
$421M
+15%
2017
$365M
-8%
2016
$397M
+41%
2015
$282M
+17%
2014
$241M
+14%
2013
$212M
+13%
2012
$187M
+15%
2011
$163M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q2 2026
$166M
Q1 2026
$444M
Q4 2025
$157M
Q3 2025
$209M
Q2 2025
$179M
Q1 2025
$410M
Q4 2024
$164M
Q3 2024
$181M
Q2 2024
$218M
Q1 2024
$348M
Q4 2023
$125M
Q3 2023
$130M
Source: ABBV on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.